Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
25.06
-0.32 (-1.26%)
At close: Mar 20, 2026, 4:00 PM EDT
24.80
-0.26 (-1.04%)
After-hours: Mar 20, 2026, 7:56 PM EDT
Alumis Employees
As of September 30, 2025, Alumis had 223 total employees, including 221 full-time and 2 part-time employees. The number of employees increased by 76 or 51.70% compared to the same quarter last year.
Employees
223
Change
76
Growth
51.70%
Revenue / Employee
$107,848
Profits / Employee
-$1,091,143
Market Cap
3.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 223 | 76 | 51.70% | 221 | 2 |
| Jun 30, 2025 | 227 | 97 | 74.62% | 225 | 2 |
| Mar 31, 2025 | 184 | 75 | 68.81% | 182 | 2 |
| Dec 31, 2024 | 170 | 61 | 55.96% | 168 | 2 |
| Sep 30, 2024 | 147 | 38 | 34.86% | 145 | 2 |
| Jun 30, 2024 | 130 | - | - | 128 | 2 |
| Mar 31, 2024 | 109 | - | - | 107 | 2 |
| Dec 31, 2023 | 109 | - | - | 107 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| ADMA Biologics | 647 |
| Denali Therapeutics | 503 |
| Dyne Therapeutics | 258 |
| Vera Therapeutics | 249 |
| Structure Therapeutics | 220 |
| Edgewise Therapeutics | 146 |
ALMS News
- 2 days ago - Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 3 days ago - Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 19 days ago - Alumis to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Alumis to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 2 months ago - Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise - Seeking Alpha
- 2 months ago - Alumis Announces Proposed Public Offering of Common Stock - GlobeNewsWire